Literature DB >> 22158486

Reduced use of chemotherapy at the end of life in an integrated-care model of oncology and palliative care.

Roberto Magarotto1, Gianluigi Lunardi, Francesca Coati, Paola Cassandrini, Vincenzo Picece, Silvia Ferrighi, Luciana Oliosi, Marco Venturini.   

Abstract

AIMS AND
BACKGROUND: When there is little hope of a clinical benefit, too delayed a withdrawal from chemotherapy might be detrimental for a patient's quality of life. We evaluated appropriately timed cessation of chemotherapy in our Oncology Department after integration of a Supportive and Palliative Care Unit.
METHODS: We carried out a review of deceased patients in our department from January 2006 to December 2009. Activities of the Supportive and Palliative Care Unit started in late 2007. We analyzed the characteristics of patients near the end of life and chemotherapy use within 30 days of death as an aggressiveness of cure index.
RESULTS: During the considered period, 361 hospitalized patients died: 69 in 2006, 77 in 2007, 97 in 2008 and 118 in 2009; 102 never received chemotherapy. Sixty-one of the remaining 259 patients died within 30 days of the last drug administration. The percentage of patients receiving chemotherapy in their last 30 days fell from 19% in 2006 and 20% in 2007, to 16% in 2008 and 14% in 2009.
CONCLUSIONS: Supportive and Palliative Care Unit integration decreased chemotherapy use in the last 30 days of life. A careful evaluation of prognostic factors of advanced cancer patients and provision of appropriate supportive and palliative cares can reduce the use of futile anticancer chemotherapy and preserve a patient's qualify of life.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22158486     DOI: 10.1177/030089161109700506

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  7 in total

1.  Chemotherapy in the last 30 days of life of advanced cancer patients.

Authors:  Paola Pacetti; Giovanni Paganini; Massimo Orlandi; Andrea Mambrini; M Cristina Pennucci; Alfonso Del Freo; Maurizio Cantore
Journal:  Support Care Cancer       Date:  2015-04-22       Impact factor: 3.603

2.  Active treatment given in the last weeks of life: poor quality cancer care or justifiable behavior?

Authors:  Gianmauro Numico; Antonio Trogu; Antonella Cristofano; Alessandro Mozzicafreddo; Giulia Courthod; Pierfrancesco Franco; Nicola Silvestris
Journal:  Support Care Cancer       Date:  2014-05-11       Impact factor: 3.603

3.  Prospective analysis of 30-day mortality following palliative chemotherapy at a tertiary cancer centre.

Authors:  James A McCracken; Adrian Dabscheck; Maria Coperchini; Ilana Hornung; Azim Jalali; Georgina Akers; Amalia Karahalios; Fran Gore; Lara Lipton
Journal:  Cancer Rep (Hoboken)       Date:  2018-09-27

4.  Time from last chemotherapy to death and its correlation with the end of life care in a referral hospital.

Authors:  Syed Mustafa Karim; Jamal Zekri; Ehab Abdelghany; Reyad Dada; Husna Munsoor; Imran Ahmad
Journal:  Indian J Med Paediatr Oncol       Date:  2015 Jan-Mar

5.  Use of chemotherapy at the end of life in Turkey.

Authors:  Sema Sezgin Goksu; Seyda Gunduz; Dilek Unal; Mukremin Uysal; Deniz Arslan; Ali M Tatlı; Hakan Bozcuk; Mustafa Ozdogan; Hasan S Coskun
Journal:  BMC Palliat Care       Date:  2014-11-19       Impact factor: 3.234

6.  Care of cancer patients at the end of life in a German university hospital: A retrospective observational study from 2014.

Authors:  Burkhard Dasch; Helen Kalies; Berend Feddersen; Caecilie Ruderer; Wolfgang Hiddemann; Claudia Bausewein
Journal:  PLoS One       Date:  2017-04-06       Impact factor: 3.240

7.  Population-based study on use of chemotherapy in men with castration resistant prostate cancer.

Authors:  Ingela Franck Lissbrant; Hans Garmo; Anders Widmark; Pär Stattin
Journal:  Acta Oncol       Date:  2013-02-21       Impact factor: 4.089

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.